A Case Report of Tragaxofusp Causing Severe Tumor Lysis Syndrome In A Patient With Blastic Plasmacytoid Dendritic Cell Neoplasm

The patient was an 83-year-old male without significant past medical hsitory who presented to his primary care physician with several days of generalized malais

A Case Report of Hemophagocytic Lymphohistiocytosis Secondary to Disseminated Tuberculosis

A 72-year-old woman with past medical history of hypertention and type 2 diabsetes presented to the emergency department for one day history of fevers, poor oral intake, and fatigue

Pericardial Effusion with Tamponade Physiology in a Patient with Multiple Myeloma

A 78-yeaer old African American female with a past medical history of IgA Kappa Multiple Myseloma was transfered to the Cardiovascular Intensive Care Unit (CVICU) at Thomas Jefferson University Hospital (TJUH) after being diagnosed with a pericardial effusion with tamponade physiology at an outside hospital

SGLT2 Inhibitors in Patients with Diabetes and Cardiovascular Disease

Problem Definition: Multiple studies (e.g. EMPA-REG, CANVAS) demonstrate that SGLT2 Inhibitors (Inh) improve cardiac outcomes in patients with Type II Diabetes (DM2) with comorbid Cardiovascular Disease (CVD) including Heart Failure and Coronary Artery Disease. SGLT2 Inhibitors are considered standard of care for patients with DM2 and CVD. Based on literature published in European Journal of Preventative Cardiology and JACC HF, our prediction is that physicians at Thomas Jefferson University Hospital Ambulatory Practices (TJUH) under-utilize SGLT2 Inh for patients with co-morbid CVD and DM2. Aims for Improvement: Within the Jefferson Healthcare System, we sought to determine: Future Interventions The percentage of patients with an indication for an SGLT2 Inhibitor who were actually being prescribed this. How often providers within the Jefferson system were prescribing these medications, and what the barriers to prescribing are. With this information, we hoped to increase the percentage of (qualifying) patients who are on these medications as part of standard of care by 20% within one year of intervention